A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain.

@article{Wallace2002AMD,
  title={A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain.},
  author={Mark S. Wallace and Michael C. Rowbotham and Gary J. Bennett and Troels Staehelin Jensen and Rosemarie Pladna and Steve Quessy},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2002},
  volume={3 3},
  pages={227-33}
}
Several lines of evidence suggest that neuropathic pain is mediated in part by an increase in the density of voltage-sensitive sodium channels in injured axons and the dorsal root ganglion of injured axons. The purpose of this study was to examine the safety, analgesic efficacy, and tolerability of oral 4030W92 (a new novel sodium channel blocker) in a group of subjects with chronic neuropathic pain. This study used a randomized, double-blind, placebo-controlled, crossover design in 41 subjects… CONTINUE READING